Please assess the completion status of the following clinical trial:

Trial Title: Creon Use in Coeliac Patients With Low Faecal Pancreatic Elastase

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with coeliac disease and having chronic diarrhoea (\>3 loose/ liquid motions a day for more than 4 weeks)~* Patients with a low faecal elastase (\<200 ug/g),~* Patients aged 16 years or over~* Patient able to give written consent to participate~* Patient not currently on Creon~Exclusion Criteria:~* Patients with normal faecal elastase (\> 201ug/g),~* Patients under the age of 16~* Patients allergic to pork or any pig product (advice from the drug manufacturer)~* Patients that are pregnant or are breast-feeding~* Patients taking alternative medication that could affect bowel frequency~* Where an alternative diagnosis for the chronic diarrhoea is established, these patients will be excluded from the trial~* Patients who are unable to speak or understand English

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Active treatment will be 2 capsules of Creon 25,000 units three times per day and the placebo will be 2 capsules three times per day; for 6 weeks treatment overall.
- Creon (Type: ACTIVE_COMPARATOR): Active treatment will be 2 capsules of Creon 25,000 units three times per day and the placebo will be 2 capsules three times per day; for 6 weeks treatment overall.

Based on this trial design, predict the completion outcome and termination type (if applicable).